Merck & Co. offers a discount of more than 30% off the list prices for its new hepatitis C treatment – Zepatier, being approved by the U.S. Food and Drug Administration. Merck said it decided that price after taking into account that most of hepatitis C patients haven’t been cured, in some situations due to cost restraints. They stated their plans to widely expose the drug across public and commercial insurers.
